secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dermata Therapeutics, Inc. (DRMA)
CIK:        0001853816
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0001654954-23-010092
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dermata auditor MHM resigns; prior audits flagged going concern; equity plan expanded
--------------------------------------------------------------------------------

- MHM will not stand for reappointment as auditor for FY2024; will serve until FY2023 audit or new auditor appointed.
- MHM's prior audit reports for FY2021 and FY2022 contained a going-concern explanatory paragraph.
- Audit committee has initiated process to select a new independent registered public accounting firm.
- Shareholders approved amendment to increase shares under 2021 Omnibus Equity Incentive Plan by 513,150 to 629,069.
- David Hale, Steven Mento, and Brittany Bradrick elected as Class II directors for three-year terms.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423010092/0001654954-23-010092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1853816/000165495423010092/drma_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-010092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer